Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

psoriatic arthritis alone or with the medicine methotrexate and active ankylosing spondylitis.

"These Phase 3 data show treatment with intravenous golimumab plus methotrexate induced and maintained improvements in the signs and symptoms of rheumatoid arthritis, and inhibited the progression of structural damage.  Such findings are encouraging for rheumatologists and patients," said Rene Westhovens, M.D., Ph.D., Professor at the Department of Rheumatology, KU Leuven, Belgium, and study investigator. "Through week 52, intravenously administered golimumab showed a consistent benefit-to-risk profile compared with previously reported week 24 data."

In the Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNF-alpha Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthritis Despite Methotrexate Therapy (GO-FURTHER), patients were randomized to receive I.V. golimumab 2 mg/kg or placebo, via a 30-minute infusion, plus methotrexate at weeks 0, 4 and then every 8 weeks.  Non-responders to placebo at week 16 were crossed over to receive I.V. golimumab, and all remaining patients receiving placebo crossed over at week 24.  Radiographic progression was assessed by the change from baseline in van der Heijde-Sharp (vdH-S) scores, an X-ray measure of joint destruction, including joint erosion and joint space narrowing in which higher scores indicate greater structural damage.  At week 24, patients receiving I.V. golimumab had a mean change (+/- standard deviation) in total vdH-S score of 0.03 (+/-1.90) from baseline, compared with a mean change of 1.09 (+/- 3.19) in the placebo group (P < 0.001).  At week 52, patients who received the 52-week regimen of I.V. golimumab had a mean change of 0.13 (+/- 3.11) from baseline, compared with a mean change of 1.22 (+/- 3.98) in patients who crossed over fr
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/pmbmv2/global_biobanking ... Biobanking Market 2015-2019" report to their offering. ... grow at a CAGR of 7.07% over the period ... divided into two segments: Equipment and Consumables. This report ... the Global Biobanking market for the period 2015-2019. ...
(Date:4/24/2015)... , April 24, 2015 Hi-Tech Pharmaceuticals ... was not the product of reliable scientific principles ... reliable basis for allegations of adulteration. The FDA ... a false premise, or misguided hope, that Methylphenylethylamine ... studies are contradicted by multiple other studies and ...
(Date:4/24/2015)... , April 24, 2015  Blueprint Medicines ... a selective and potent inhibitor of fibroblast growth ... in models of hepatocellular carcinoma (HCC) that are ... candidate, BLU-554 induced complete tumor regression in a ... FGFR4-activating ligand at the highest dose levels. These ...
Breaking Medicine Technology:Global Biobanking Market Report 2015-2019 - Increase in Strategic Collaborations with Beckman Coulter, Tecan & Thermo Fischer Scientific Dominating 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3
... score of 94.4 out of 100, Elekta,s Leksell Gamma Knife® ... top among six advanced radiation therapy systems, according to KLAS ... A Dose of New Technology . The Elekta Infinity™ ... score of 84.4, improving its score over the 2010 report. ...
... 9 , 2011  OncoSec Medical Incorporated (OTCBB: ... therapies to treat skin cancer and other solid ... and CEO, will be presenting at the 22nd ... http://photos.prnewswire.com/prnh/20110314/MM64943LOGO ) 22nd Annual ...
Cached Medicine Technology:Elekta's Leksell Gamma Knife Perfexion Earns Nearly Perfect Score in 2011 KLAS Radiation Therapy Report 2OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference 2OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference 3
(Date:4/26/2015)... Lauderdale, FL (PRWEB) April 26, 2015 ... 1,200 pieces of medical equipment from hospitals, surgery centers ... types of equipment will be sold including radiology, surgery, ... The live auction will take place Tuesday, April 28th ... Fort Lauderdale warehouse located at 5025 North Hiatus Rd., ...
(Date:4/26/2015)... In an article published last month ... head-neck biomechanics occurring during the use of handheld electronic devices ... determine that use of a tablet increases mechanical demand on ... - more than when the neck is in a neutral ... but pointing out the potential hazards of overuse of mobile ...
(Date:4/26/2015)... April 26, 2015 MidSouth Pain ... throughout the Southeast. MidSouth Pain Treatment Center is a ... Cordova, Southaven, Oxford and Jackson, two ambulatory surgery centers ... the Southaven and Cordova locations. , Dr. Michael ... went into medicine to help people, and when I ...
(Date:4/25/2015)... Avid Collector Andrew Hawley from Vintage Rock ... Coliseum concert posters. The concert was held on 12 ... American Tour. , According to Hawley, “The poster ... Maryland. This poster blank was used to advertise the ... uses garish lettering and colors on this boxing style ...
(Date:4/25/2015)... Jersey (PRWEB) April 25, 2015 In ... aged twelve and above needed treatment for an ... to the Substance Abuse and Mental Health Services Administration’s ... 2011). Beyond these alarming numbers are harrowing stories of ... substance abuse . David H. Kerr , ...
Breaking Medicine News(10 mins):Health News:Centurion Service Group to Auction off 1,200 Lots of Medical Equipment 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 2Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 3Health News:Avoiding the Pain in the Neck Caused by Overuse of Technology 4Health News:Growing Pains for MidSouth Pain Treatment Center 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 2Health News:New Book Features Powerful Stories of People Who Overcame Addiction 3
... News) -- People affected by epilepsy are nearly eight ... schizophrenia, and those with schizophrenia are also six times ... not schizophrenic, a new study suggests. Researchers in ... may be due to genetic, environmental or neurobiological causes. ...
... the Mining Microbial Genomes for Novel Antibiotics research theme ... a recipient of the 2011 National Institutes of Health ... from some of the nation,s most promising new scientists. ... of five years, supports young investigators who have proposed ...
... Talking with doctors about cancer and cancer treatments can feel ... often need help to understand their treatment options, and the ... making life and death decisions that may affect their survival ... Cancer treatments and tests can be serious. Patients need to ...
... DURHAM, N.C. An analysis of more than 30,000 cancer ... complication than doctors may realize, causing additional hospitalizations and driving ... by a Duke Cancer Institute researcher. The study, which ... Cancer Congress in Stockholm, found that as many as one ...
... based method of family planning developed by researchers from ... so effectively meets the needs of users that they continue ... finds that women who follow the Standard Days Method, are ... effectively. Results of the large, multi-country study of 1659 women ...
... new type of nanoparticle developed in the laboratories at the ... delivery of chemotherapy to treat cancer. Wenbin Lin, PhD, ... their finding in the Sept. 14, 2011 issue of ... laboratory studies, Lin and colleagues developed and tested a new ...
Cached Medicine News:Health News:Researchers Find Link Between Epilepsy, Schizophrenia Risk 2Health News:10 ways to make better decisions about cancer care 2Health News:10 ways to make better decisions about cancer care 3Health News:Costly blood clots more common than expected among cancer patients 2Health News:Long-term effectiveness of new family planning method shown in study 2Health News:UNC scientist proves potential of new nanoparticle design for cancer therapy 2
Reliavac® 400cc kits with siliconized PVC drain, Y-connector tube...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used with T-tubes to collect drainage after cholecystectomy. Includes T-tube adapter and two adjustable latex rubber belts....
Used following hysterectomy procedure. Often attached to Bard bile bag....
Medicine Products: